 Todos Medical Ltds majority-owned subsidiary 3CL Pharma Ltd has provided a Day 45 update from its ongoing case study of Tollovid, a 3CL protease inhibitor dietary supplement, for a patient with long COVID. The company said the patient, a healthy, 46-year-old unvaccinated male originally contracted COVID in February 2021 and has since exhibited a range of long COVID symptoms including feeling dizzy, head pressure, sleep disturbance, tachycardia, pain in his throat, and difficulty swallowing for which the subject sought treatment and diagnostic testing from several medical specialists. 